A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
312actual
Sites
88
Countries
Denmark, France, Germany +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-11-25 | actual | When the study began enrolling |
| Primary completion | 2025-12-10 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2020-11-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Migraine
Interventions
- Drug: Galcanezumab — also filed as LY2951742
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from Baseline in the Number of Monthly Migraine Headache Days
measured Baseline, 3 Months
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed